Anagrelide (Agrylin)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.[1][2]
Route: PO
Extravasation: n/a

  • Example of usage: Anagrelide (Agrylin) 0.5 mg PO 4 times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

Also known as

  • Brand names: Agrylin, Xagrid

References

  1. 1.0 1.1 Anagrelide (Agrylin) package insert
  2. Anagrelide (Agrylin) package insert (locally hosted backup)
  3. Anagrelide (Agrylin) patient drug information (Chemocare)
  4. Anagrelide (Agrylin) patient drug information (UpToDate)